1h Free Analyst Time
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report GMDHC22213TDB, outlays comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Cell division cycle 7-related protein kinase is an enzyme encoded by the CDC7 gene. It phosphorylate substrates that regulate the G1/S phase transition and DNA replication. Overexpression of CDC7 is associated with neoplastic transformation for some tumors. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Colorectal Cancer, Metastatic Colorectal Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Cervical Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Rectal Cancer, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.
Furthermore, this report also reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)
- The report reviews Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Overview
- Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
- Carna Biosciences Inc
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Eli Lilly and Co
- Lin Bioscience Inc
- Millennium Pharmaceuticals Inc
- Schrodinger Inc
- Takeda Pharmaceutical Co Ltd
- Zai Lab Ltd
- Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Drug Profiles
- AS-0141 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LBS-007 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LY-3143921 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SDGR-1 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- simurosertib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- simurosertib - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit CDC-7 for Pancreatic Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit CDC7 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit CDc7 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- TQB-3824 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Dormant Products
- Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Discontinued Products
- Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Product Development Milestones
- Featured News & Press Releases
- Nov 03, 2022: Schrodinger to present new preclinical data from its CDC7 inhibitor program at American Society Of Hematology 2022 Annual Meeting
- Mar 08, 2022: Schrödinger to present new preclinical data from its Wee1 inhibitor program at AACR Annual Meeting 2022
- Apr 12, 2021: Schrödinger reports preclinical data on novel, selective CDC7 inhibitors presented at American Association for Cancer Research Annual Meeting
- Mar 30, 2021: Schrödinger to host webcast in conjunction with presentation of preclinical data for its CDC7 program at virtual AACR annual meeting
- Mar 10, 2021: Schrodinger announces preclinical data for CDC7 program to be presented at AACR Virtual Annual Meeting 2021
- Apr 03, 2019: Sierra reports late-breaking SRA141 preclinical data in poster at AACR 2019
- Feb 27, 2019: Sierra Oncology announces late-breaking poster presentation at AACR 2019 for SRA141 preclinical data
- Nov 13, 2018: Sierra Oncology reports SRA141 preclinical efficacy at EORTC-NCI-AACR symposium
- Nov 09, 2018: Successful Completion of IND filing with FDA for SRA141
- Apr 24, 2018: Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia
- Feb 27, 2018: Sierra Oncology Provides Update on SRA141
- Feb 06, 2018: Sierra Oncology to host program update on SRA141 on February 27th in New York
- Aug 23, 2017: Cancer Research UK launches trial to test new drug in patients with advanced cancer
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Carna Biosciences Inc, 2022
- Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
- Pipeline by Eli Lilly and Co, 2022
- Pipeline by Lin Bioscience Inc, 2022
- Pipeline by Millennium Pharmaceuticals Inc, 2022
- Pipeline by Schrodinger Inc, 2022
- Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Pipeline by Zai Lab Ltd, 2022
- Dormant Projects, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Carna Biosciences Inc
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Eli Lilly and Co
- Lin Bioscience Inc
- Millennium Pharmaceuticals Inc
- Schrodinger Inc
- Takeda Pharmaceutical Co Ltd
- Zai Lab Ltd
